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Abstract
Herein, a new method for the detection of 13 different pharmaceuticals and one metabolite in surface water at low ng/L levels is described.
The method utilizes ultra performance liquid chromatography–tandem mass spectrometry and a solid-phase extraction sample preparation. Mean
method detection limits were low (4.10 ng/L) and overall solid-phase extraction recovery and reproducibility was adequate (mean recovery, 77.9%;
mean RSD, 7.3%). The method allows for quick run times and minimal solvent use as compared with other previously reported high performance
liquid chromatography-based methods. Application of this method for the detection of pharmaceuticals in Tennessee River surface water determined
that caffeine, sulfamethoxazole, and carbamazepine were frequently detected (100% of samples). Trimethoprim was moderately detected (30%
of samples); acetaminophen, atorvastatin, and lovastatin were infrequently detected (10% of samples); and ciprofloxacin, diltiazem, fluoxetine,
levofloxacin, norfluoxetine, ranitidine, and sertraline were not detected. This study reports the first detection of lovastatin in surface water.
© 2008 Elsevier B.V. All rights reserved.
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1. Introduction
It is well established that the source, presence, and fate of
pharmaceutically active compounds in the aquatic environment
is of concern [1–5]. This area of research has progressively
received more attention as the ubiquity of many pharmaceu-
ticals in surface water becomes evident. Currently more than
80 pharmaceutical compounds have been detected in sewage
effluent, surface water, and groundwater in at least 12 different
nations; the majority of studies were in Europe and North Amer-
ica [4,6]. A national U.S. reconnaissance study by Kolpin et al.
[7] analyzed for pharmaceutical residues in surface waters of 33
states and smaller scale studies have been conducted in Iowa [8],
Louisiana [9], and Nevada [10]. In each study, detectable levels
of a variety of pharmaceuticals were reported. As of 2006, Ten-
nessee is third in the nation for retail prescription drugs filled at
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pharmacies at 15.8 per capita and 15th in the nation for total pop-
ulation [11]. Despite the high per capita usage rate and relatively
high population, no currently published studies have examined
Tennessee waters for pharmaceutical contamination.
The toxicological effects of pharmaceuticals in the environ-
ment to humans and free living aquatic and terrestrial organisms
are not well understood. Of particular concern are the poten-
tial impacts on aquatic organisms that may experience subtle,
chronic life-cycle and multi-generational exposure to low doses
of pharmaceuticals [2,5]. In order to elucidate these environ-
mental and ecological impacts, there is a need for analytical
methods that allow quantitation of pharmaceuticals in aquatic
matrices [2,3,5]. Ideally these methods should be simple, rapid,
sensitive, selective, broad spectrum, and able to overcome the
negative effects of matrix components.
The most widely used instrumentation for determining con-
centrations of trace pharmaceuticals in environmental samples
is liquid chromatography–tandem mass spectrometry (LC–MS/
MS) coupled with a solid-phase extraction (SPE) sample prepa-
ration step. The popularity of this procedure is due to the
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selectivity and sensitivity of LC–MS/MS and the ability of
diverse SPE sorbent chemistries to bind a wide variety of
molecules [12–14]. Numerous studies have successfully uti-
lized LC–MS/MS to detect pharmaceutical residues in sewage
treatment plant (STP) influent and effluent, surface water,
and groundwater after sample pre-concentration using SPE
[15–25]. Pharmaceutical residues are consistently analyzed
down to the low ng/L level with drawbacks being matrix
effects and separation difficulties for highly polar compounds
[12].
The objective of this study was to develop a LC–MS/MS
method for the determination of a broad spectrum of commonly
used pharmaceuticals in surface water. Further, it was in the
authors’ interest to make the method as accurate, precise, simple,
and cost-effective as possible without compromising sensitivity.
To this end, a SPE sample pre-concentration coupled with a
LC–MS/MS method for separation and detection of 13 different
pharmaceuticals and 1 primary metabolite has been developed.
The utility and ability of this method was applied to samples of
surface water collected from the Upper Tennessee River Basin
located in eastern Tennessee.
Selection of pharmaceutical compounds for method devel-
opment was based on compounds previously used in a
study on the effects of pharmaceuticals in aquatic meso-
cosms (acetaminophen, atorvastatin, caffeine, carbamazepine,
ciprofloxacin, fluoxetine, levofloxacin, sertraline, sulfamethox-
azole, and trimethoprim) [26,27]. Pharmaceuticals were chosen
for that study based on the estimated usage rate inferred from the
number of prescriptions dispensed per year in the U.S. [28], and
commonly consumed non-prescription drugs (acetaminophen
and caffeine). Diltiazem, lovastatin, and ranitidine were chosen
based on ionization potential (electrospray positive compounds)
and number of prescriptions dispensed per year in the U.S. [28].
Norfluoxetine was chosen because it is a primary metabolite
of fluoxetine and has the potential to be more prevalent than
its parent molecule. Overall, the goal was to have a variety of
pharmaceuticals representing prescription and non-prescription
classes. Selections for the method resulted in eight differ-
ent major pharmaceutical classes being represented (analgesic,
antibiotic, antiepileptic, antidepressant, antihypertensive, lipid
regulator, stimulant, antihistamine) and one primary metabolite
(Table 1).
2. Experimental
2.1. Pharmaceutical standards and reagents
All pharmaceutical compounds were of 95% purity or bet-
ter and used as received in solid form. 4-Acetamidophenol,
carbamazepine, (+)-cis-diltiazem hydrochloride, norfluoxetine
hydrochloride, ranitidine hydrochloride, and sulfamethoxazole
were obtained from Sigma (St. Louis, MO, USA). Caffeine was
obtained from Alfa Aesar (Ward Hill, MA, USA). Trimetho-
prim was obtained from Bufa (Uitgeest, Holland). Atorvastatin
and lovastatin were obtained from Rugao (Shanghai, China).
Levofloxacin was obtained from Zhejiang Wonderful Pharma
& Chemical (Zhejiang, China). Sertraline was obtained from
Ranbaxy Laboratories (New Delhi, India). The internal standard
(IS), 13C-caffeine was obtained from Isotec (Miamisburg, OH,
USA) and received as a 1.0-mg/mL solution in pure methanol
(MeOH).
Ultrapure water (MQ) was of 18.2 M cm purity and sup-
plied by a Direct-Q 3 UV system (Millipore, Billerica, MA,
USA). All organic solvents (acetonitrile (ACN), MeOH, and
isopropanol (IPA)) were Optima grade purity (Fisher Scientific,
Pittsburgh, PA, USA) and 99% pure formic acid (FA) was pur-
chased from Acros Organics (Morris Plains, NJ, USA). Stock
solutions of standards were made by weighing out approxi-
Table 1
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mately 100 mg (three significant figures) solid standard of each
drug and dissolving in 1.0 L of a 50:50 mix of MQ:ACN.
The stock solution was subsequently 0.22m filtered into an
amber glass vial and stored at 4 ◦C. Working solutions were
prepared daily by dilution of stock solution into a mix of 85:15
MQ:ACN + 0.1% FA. Stock solutions were kept no longer than
3 months and prepared fresh as needed for sample quantitation.
2.2. Sample collection
Surface water samples were collected from the Upper Ten-
nessee River Basin 12–13 December 2006. Samples were
collected as a composite of three vertical profiles from the river
cross-section with 500 mL aliquots being collected equidistant
from the right bank and left bank and from the center of the
river. Aliquots were homogenized and 1.0 L was transferred
to an amber HDPE bottle and placed on ice. Sample bottles
were cleaned prior to sampling by triple rinsing with a 50:50
mix of MeOH:IPA and with MQ. Within 12 h samples were fil-
tered through 47 mm, 0.77m glass fiber filters conditioned with
approximately 10 mL of a 50:50 mix of MeOH:IPA and 10 mL of
MQ. Samples were additionally passed through 47 mm, 0.45m
membrane filters and then frozen at −80 ◦C until analysis.
2.3. Sample preparation
Samples were removed from the freezer and allowed to thaw
to room temperature gradually (∼16 h). Bottles were homog-
enized and exactly 500 mL were transferred to a volumetric
flask and amended with 50L of a 1.0-mg/L solution of 13C-
caffeine IS (final conc., 100 ng/L). Analytes were concentrated
using Waters (Milford, MA, USA) Oasis hydrophilic–lipophilic
balanced (HLB), 60 mg, 3 mL SPE cartridges in batches of 8.
Cartridges were mounted in a vacuum manifold fitted with poly-
tetrafluoroethylene (PTFE) stopcock/needles. Each cartridge
was conditioned with 3 mL MeOH followed by 3 mL MQ.
Samples were then drawn through the cartridges at a rate of
approximately 10 mL/min using PTFE transfer tubes. After sam-
ple loading was complete, sample flasks and transfer tubes were
rinsed with 10 mL of MQ and the rinsate was passed through
the SPE cartridge. A wash step of 3 mL of MQ was then passed
through the SPE cartridges. Cartridges were then dried under
vacuum for 15 min.
Dried cartridges were transferred to a modified elution cham-
ber consisting of a 16 mm × 100 mm glass test tube with a LC
sample vial inserted. Analytes were eluted using 500L of
MeOH followed by 500L of acidified MeOH (0.5 M FA). Each
solvent was allowed to drip through the cartridge under gravity
for 10 min. Elution chambers were then centrifuged for 2 min to
maximize analyte recovery. Sample vials were then evaporated
to dryness under a gentle stream of nitrogen gas at room tem-
perature. Dried sample vials were reconstituted with 500L of
sample diluent (85:15 MQ:ACN + 0.1% FA), resulting in a 1000-
fold concentration of analytes. If instrumental analysis could not
be completed immediately, sample vials were frozen at −20 ◦C
until they could be analyzed, typically within 48 h.
Quality control was monitored through field blanks, which
consisted of two 500 mL aliquots of MQ being handled in the
same manner as field samples. Additionally, method blanks and
method spikes were processed without contact to the field sam-
pling equipment. Method blanks consisted of MQ amended with
the IS, and method spikes consisted of MQ spiked with either
50 or 100 ng/L of all analytes as well as the IS. One method
blank and one method spike was analyzed to monitor for con-
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tamination and recovery of analytes from the sample preparation
procedure.
2.4. Chromatography and mass spectrometry
Separation of compounds was carried out using a Waters
Acquity ultra performance liquid chromatograph (UPLCTM)
fitted with a 50.0 mm × 2.1 mm, bridged-ethyl-siloxane/silica
hybrid (BEH) Shield RP-C18 column coupled with a 30.0-mm
C18 guard column. Separation was achieved using a step-wise
binary elution gradient consisting of 95:5 MQ:ACN + 0.1%
FA as the aqueous phase (A) and ACN + 0.1% FA as the
organic phase (B). The gradient was as follows: 5% B held
for 0.70 min, increased linearly to 30% B in 0.10 min, then
a gradual increase to 35% B over 1.00 min, followed by an
increase to 95% B in 0.1 min and held for 0.3 min, finally a
return to initial conditions of 5% B over 0.25 min and held for
0.80 min to allow for equilibration before the next injection.
All flow was directed into the mass spectrometer. Additional
parameters were as follows: flow rate, 0.400 mL/min; injection
volume, 5L; column temperature, 40 ◦C; sample temperature,
25 ◦C.
The UPLC was interfaced to a Quattro Micro API triple-
quadrupole mass spectrometer (Micromass, Manchester, UK)
with an electrospray ionization (ESI) source. The mass analyzer
operated in positive ionization mode for all analytes and ESI
source conditions were as follows: source temperature, 130 ◦C;
desolvation temperature, 400 ◦C; cone gas, 25 L/h; desolvation
gas, 750 L/h; capillary voltage, 0.7 kV; multiplier, 650 V. Nitro-
gen (99.995% purity, Airgas) was used as the desolvation and
nebulization gas, and ultra-pure argon (99.999% purity, Airgas)
was used as collision gas.
To determine the mass transitions of analytes, a 100-g/L
solution of each compound was infused directly into the mass
spectrometer at 10L/min. The flow path was modified with
a T-mixer, which allowed LC mobile phase to be simulta-
neously infused with the sample solution. This allowed the
analytes to reach the ESI source under similar conditions
as those that would be encountered during a typical sample
analysis. For all analytes the precursor ion corresponding to
m/z [M+H]+ was determined to be the most dominant ion,
except for lovastatin for which m/z [M+Na]+ was the most
dominant ion. The most abundant product ions were deter-
mined by adjusting the collision cell energy and pressure of
argon in the collision cell. Table 2 reports the mass tran-
sitions, cone, and collision energies used for each of the
analytes.
2.5. Quantitation
The standard addition method was used to quantify all ana-
lytes. Briefly, each reconstituted sample was separated into four
equal aliquots (125L). The order of the four vials was random-
ized in the sample plate to discourage any biases created from
pipetting. Each vial was then amended with a 12.5-L aliquot of
standard solution. Specifically, vial 1 was amended with sample
diluent containing no analytes, vial 2 was amended with a 10.0-
g/L solution of each of the analytes, vial 3 with a 100.0-g/L
solution, and vial 4 with a 1000.0-g/L solution. Samples were
injected in triplicate and in increasing concentration order with
two blanks injected between samples to minimize carryover. All
peak data was acquired using Mass Lynx software (Version 4.1,
Waters Corp.).
Analytes were detected using multiple reaction monitoring
(MRM) mode for the appropriate mass transitions. MS method
parameters include: inter-channel delay, 30 ms; inter-scan delay,
30 ms; repeats, 1. The dwell time varied for each analyte,
depending on the number of analytes within a given time frame,
to allow for an adequate number of scans (≥12) to resolve the
peak. Mass spectrometry dwell times were either 50 ms (dilti-
azem, norfluoxetine, fluoxetine, sertraline, sulfamethoxazole),
100 ms (acetaminophen, trimethoprim, caffeine, 13C3-caffeine,
levofloxacin, ciprofloxacin, lovastatin), or 200 ms (ranitidine,
carbamazepine, atorvastatin).
Table 2
Mass spectrometric parameters for detection of pharmaceutical compounds
Time (min) Analyte Precursor ion (m/z) Product ion (m/z) Cone (V) Collision (V)
0.42 Ranitidine 315.15 176.10 25 17
0.79 Acetaminophen 152.00 109.70 30 16
0.80 Trimethoprim 291.15 230.30 38 24
1.05 Caffeine 195.00 138.00 34 20
1.05 13C-Caffeine 198.00 139.90 35 19
1.11 Levofloxacin 362.20 318.30 32 18
1.28 Ciprofloxacin 332.20 288.30 34 16
1.36 Diltiazem 415.20 178.10 32 24
1.48 Norfluoxetine 296.10 133.90 14 6
1.52 Fluoxetine 310.10 148.00 19 9
1.55 Sertraline 306.10 275.20 17 13
1.54 Sulfamethoxazole 254.10 155.90 26 16
1.87 Carbamazepine 237.10 194.20 30 19
2.47 Atorvastatin 559.20 440.35 34 22
2.58 Lovastatin 427.10a 325.30 42 22
Retention time and appropriate mass transition were used to positively identify compounds by monitoring for the protonated form of the molecule [M+H]+ unless
otherwise noted. 13C-Caffeine—internal standard.
a [M+Na]+.
Author's personal copy
J.M. Conley et al. / J. Chromatogr. A  1185 (2008) 206–215 211
All peak integration and analysis was performed using Quan-
Lynx (Version 4.1, Waters Corp.). Peaks were smoothed using
mean smoothing with one iteration. A response factor ((sample
peak area) × (IS conc./IS area)) was calculated for each peak
using the IS to correct for small variations. Response factors
were used to generate a linear regression (y = mx + b) with 1/x
weighting and excluding the origin. Analyte concentrations were
determined by taking the absolute value of the intercept (b)
divided by the slope (m) and applying the 1000-fold concen-
tration factor to finish with units of ng/L.
3. Results and discussion
3.1. Chromatographic method
A variety of solvents were tested during the development
of the elution gradient. These included MeOH and ACN for
the B channel, and 0.5 mM ammonium acetate, pure MQ, and
combinations of organic solvent + MQ for the A channel. It was
determined that the combination of 95:5 MQ:ACN (A channel)
and ACN (B channel), each with 0.1% FA added, provided the
most efficient separation and best peak shape for all analytes in
the method in a favorably short run time.
Trials indicated that MeOH was not a strong enough elution
solvent due to extended retention times of the most nonpolar
compounds, and peak broadening or overall poor peak shape
for the most polar compounds. Having 5% ACN in the aqueous
channel helped to reduce the influence of pressure spikes on col-
umn during the rapid, step-wise changes in the elution gradient.
Formic acid improved peak shape and area by providing a source
of protons to aid in the overall ionization efficiency of the source.
The goal of the chromatographic separation was to resolve
peaks while having an adequate number of scans across each
peak (≥12 scans) in the shortest time frame possible, while
retaining acceptable peak shape. Due to the variety of physic-
ochemical properties displayed by the analytes, including large
differences in polarities, it was determined a step-wise binary
elution gradient would be the most efficient. The most polar
molecules (ranitidine, acetaminophen, trimethoprim, caffeine)
were eluted during the initial gradient step (5% B). Next, the
moderately nonpolar molecules (ciprofloxacin, levofloxacin,
diltiazem, norfluoxetine, fluoxetine, sertraline, sulfamethoxa-
zole, and carbamazepine) were eluted during the second step
(30–35% B). Finally, the most nonpolar molecules (atorvastatin
and lovastatin) were eluted during the third step (90% B). Tests
were done with a purely linear elution gradient, but this resulted
in run times of up to 12 min. By quickly ramping (0.1 min) the
change in B channel between gradient steps, all analytes were
adequately separated and eluted to the detector in 3.25 min,
including a return to initial conditions and a 0.8-min column
equilibration step before the next sample was injected.
3.2. Mass spectrometry
All precursor ions determined here were essentially iden-
tical to those reported in other LC–MS/MS methods for
the compounds acetaminophen, atorvastatin, caffeine, carba-
mazepine, ciprofloxacin, diltiazem, fluoxetine, levofloxacin,
norfluoxetine, ranitidine, sertraline, sulfamethoxazole, and
trimethoprim [15,17,18,21,23,24,29,30]. Product ions varied
among other published methods but similar complete mass tran-
sitions were reported for each drug including acetaminophen
[17,21,24,26,29], atorvastatin [16], caffeine [17,18,26,29], car-
bamazepine [17,21–24,26,29,30], ciprofloxacin [22], diltiazem
[18,29,30], fluoxetine [29,31], levofloxacin [26], norfluoxetine
[29], sertraline [26,29], sulfamethoxazole [17,18,26,29,30], and
trimethoprim [15,21,24,30]. Several studies had similar precur-
sor ions, but dissimilar product ions than those used in this
method, including sulfamethoxazole [15,24], fluoxetine [17],
trimethoprim [17,18,23], and ciprofloxacin [30]. Lovastatin was
found in the literature to have a different mass transition (m/z
436 > 285) than reported for this method [16]. To our knowledge,
the mass transition used for the determination of lovastatin has
not been published previously.
3.3. Solid-phase extraction—sample loading
Oasis HLB SPE cartridges are commonly used for
analysis of pharmaceuticals in environmental matrices
[16–18,20–24,32,33]. Few studies indicate the reasoning for
utilizing one mass of HLB sorbent versus another. Typically
the concern is whether the given sorbent mass has the capacity
to effectively retain the analytes of choice without overloading
the active sites. A simple breakthrough study was conducted to
determine analyte retention when loading onto a 60-mg Oasis
HLB cartridge. Two 500 mL aliquots of MQ, spiked at 100g/L
for all analytes, were loaded on pre-conditioned 60 mg Oasis
HLB cartridges at 10 mL/min. All filtrate for each cartridge
was collected separately and breakthrough was quantified by
comparing the signal of a sample of the spiked water prior to
cartridge loading to a sample of the collected filtrate. With the
exception of acetaminophen, ranitidine, and caffeine, all drugs
displayed less than 1% breakthrough. Acetaminophen displayed
a mean breakthrough of 44.7%, ranitidine 2.09%, and caffeine
1.69%. It is assumed that these analytes were less adequately
retained due to their high polarity relative to the other analytes.
The second test of cartridge efficacy was based on the pH of
the sample (data not shown). Duplicate MQ spikes (100 ng/L)
were prepared at pH 2, 7, and 10 using concentrated sulfuric acid
or sodium hydroxide. The recoveries indicated that at pH 2 raniti-
dine was essentially not recovered, most likely due to molecular
ionization at this pH and subsequent breakthrough of the SPE
sorbent. Other drugs, including ciprofloxacin, diltiazem, ser-
traline, fluoxetine, and norfluoxetine displayed higher average
recoveries at pH 2 than the other pHs. At pH 10 sulfamethox-
azole, acetaminophen, and lovastatin displayed low recoveries,
most likely because of poor retention due to molecular ionization
or inadequate elution. Further, at pH 10 norfluoxetine, fluoxe-
tine, sertraline, and diltiazem displayed reduced recoveries as
compared to the other pHs. At pH 7 no compounds displayed
dramatic adverse effects and, in many instances, recoveries were
as good or better than the other pHs. For this reason, pH 7 was
chosen for sample preparation and environmental samples were
not amended with acids or bases.
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Therefore, it was determined that 60 mg HLB cartridges
provided adequate retention at neutral pH for the majority of ana-
lytes. Acetaminophen displayed a relatively large breakthrough
(∼45%) but in order to achieve the most optimum retention for
a broad spectrum of analytes, it is necessary to make decisions
that might adversely affect one or more of the compounds. In
this case, acetaminophen is commonly found in the environment
in relatively high concentrations [7,24] so a low recovery is not
seen as an unjustifiable hindrance to quantitation. Further ver-
ification for the use of 60 mg HLB cartridges can be seen in a
number of other studies which utilize this cartridge and have
achieved adequate recoveries (generally 60–100%) [22–24,32].
Additionally, 60 mg HLB cartridges are the least costly (two- to
fourfold less) of the Oasis HLB syringe-type SPE cartridges.
3.4. Solid-phase extraction—sample elution
As previously described, it was observed that the majority of
analytes were fully retained on the HLB sorbent and thus, could
potentially be completely eluted. A variety of organic solvents
were tested for elution efficiency including: MTBE, MeOH, IPA,
ACN, hexane, and ethanol. It was determined that MeOH was
the most adequate for eluting analytes using minimal elution
volumes. This elution process is similar to the one utilized by
Lam et al. [26] for a similar array of analytes.
The use of a small volume of elution solvent allowed the elu-
ent to be collected directly into a LC sample vial. This helped
eliminate the error associated with passing the eluent through
the PTFE stopcock/needle unit and reducing the number of
glassware and sample transfers during elution, evaporation, and
reconstitution steps. It could be argued that the low recovery
for a number of analytes (<70% for: ranitidine, acetaminophen,
sulfamethoxazole, atorvastatin, and lovastatin) was due to inad-
equate elution solvent volume to remove all analytes. This is
most likely true, however it is not seen as a hindrance due to the
acceptable reproducibility (RSDs ≤ 16%) for recovery of ana-
lytes across multiple days (n = 3). Further, the amount of elution
solvent employed in this method is four- to eightfold less than
in other published methods using the same SPE cartridge in a
similar context [22–24].
3.5. SPE recovery and matrix effect
Analyte recovery was determined using assessment tech-
niques similar to those outlined by Matuszewski et al. [34] for
dealing with complex matrices. Surface water was collected
from the Tennessee River at a site upstream of any known
sewage treatment plant discharge points to reduce the interfer-
ence of ambient pharmaceutical concentrations. On each of 3
days, 4× 1000 mL samples were collected from the river and
filtered according to experimental procedure. Filtered samples
were homogenized in a 4000-mL amber glass jug and separated
into 8× 500 mL volumetric flasks. Four flasks were amended
with 50L of a 1.0-mg/L mixture (0.1g/L final conc.) of all
analytes (Set 1) and the remaining four flasks were amended
with 50L of pure sample diluent (Set 2). All eight samples
were taken through the sample preparation procedure except for
Set 2 samples, which were reconstituted with 500L of a 100-
g/L mixture of all analytes. Sets 1 and 2 samples were analyzed
and recovery was determined for each analyte using peak areas




Mean Set 2 Area
)
× 100
Recovery was assessed for reproducibility each day (intraday
reproducibility) and across days (interday reproducibility). The
overall recovery of the method as reported in Table 3 is the
interday reproducibility, as this is seen as a better qualifier of the
robustness of the method. To determine interday reproducibility,
the entire set of recoveries (n = 12) was averaged for each drug
and %RSD calculated.
The majority of the molecules that elute in the mid-
dle of the LC gradient (trimethoprim, caffeine, levofloxacin,
ciprofloxacin, diltiazem, norfluoxetine, fluoxetine, sertraline,
carbamazepine) display very good recoveries (range, 71.5–
104.9%). Acetaminophen was observed to suffer a low recovery
(52.8%) but this can be explained by the significant break-
through (∼45%) of the SPE sorbent. The remaining molecules
displaying low recovery (ranitidine, sulfamethoxazole, atorvas-
tatin, lovastatin) are most likely due to incomplete desorption
from the SPE sorbent during the elution step.
Matrix effect was determined parallel to the recovery study.
In addition to Sets 1 and 2 described above, Set 3 consisted of
a 100-g/L solution of all analytes in neat sample diluent. To
assess percent matrix effect for each analyte, peak areas were
used with the following equation:
Matrix Effect (%) =
((
Mean Set 2 Area





This equation is similar to that described by Matuszewski et
al. [34], but has been slightly modified as stated by Clodfelter
[35]. A negative (−) value indicates matrix suppression and a
positive (+) value indicates matrix enhancement. It was observed
that all analytes suffered from matrix suppression (range, −8.7
to −79.3%; mean, −35.0%), most likely from analyte compe-
tition for protonation at the ESI source with constituent matrix
components. Table 3 presents the instrumental limitations and
method limitations, recovery, and matrix effect.
3.6. Calibration and quantitation
Numerous studies have been performed explicitly to deal
with matrix effects when quantifying compounds in environ-
mental samples using LC–MS/MS [36–40]. Proposed methods
involve extensive sample clean-up during sample preparation,
decreased flow or flow splitting of mobile phase into the MS
source, and dilution of samples prior to injection. Each of
these methods typically results in a reduction in matrix effect
but, consequently, a decrease in analyte signal at the detec-
tor or reduced SPE recovery may occur. Isotopically labeled
ISs are also frequently utilized but unless there is an IS con-
gruent to each analyte in the method, the researcher is taking
a potentially invalid assumption that the matrix is affecting
the analyte in an identical way to the ISs. Further, com-
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Table 3
Instrumental limitations and method parameters of efficacy
Analyte Instrumental Method
LOD (pg) LOQ (pg) MDL (ng/L) Recovery (%RSD) Matrix effect (%)
Ranitidine 0.271 0.900 1.77 64.3 (8.7) −28.7
Acetaminophen 1.27 4.22 2.06 52.8 (14.2) −25.1
Trimethoprim 0.320 1.07 2.26 96.7 (4.2) −8.7
Caffeine 0.990 3.30 17.7 95.3 (2.9) −14.6
Levofloxacin 0.481 1.61 5.95 104.9 (9.5) −11.3
Ciprofloxacin 0.550 1.84 4.51 93.6 (7.5) −49.5
Diltiazem 1.04 3.45 1.25 88.3 (4.0) −37.0
Norfluoxetine 0.0452 0.151 1.84 71.5 (4.7) −42.4
Fluoxetine 0.815 2.72 3.29 80.1 (3.6) −38.0
Sertraline 0.472 1.57 1.92 80.6 (3.0) −47.3
Sulfamethoxazole 0.295 0.980 2.97 54.9 (10.3) −41.0
Carbamazepine 0.317 1.06 2.85 99.3 (2.2) −18.9
Atorvastatin 0.620 2.07 2.24 42.0 (11.3) −47.8
Lovastatin 0.505 1.69 6.53 67.0 (16.2) −79.3
Instrumental limit of detection (LOD) and quantitation (LOQ) based on signal to noise of 3 and 10, respectively. Method detection limit (MDL) as defined by EPA
[40] (n = 10); recovery and matrix effect determined similar to Matuszewski et al. [34]. RSD: relative standard deviation; pg: picograms of analyte on-column.
mercially available ISs do not exist for all commonly used
pharmaceuticals, including a number of analytes found in this
study and, when available, can be considerably cost inten-
sive.
Standard addition is widely viewed as the only accurate alter-
native to comprehensive internal standardization for quantifying
analytes in complex matrices using LC–MS/MS [36,37]. Stan-
dard addition is seen as being time consuming and laborious,
but it is able to compensate for matrix interference given a sam-
pling paradigm covering a broad area with wide variation in
matrix components and a lack of available isotopically labeled
standards.
Due to the relatively high degree of matrix suppression
(mean, −35.0%), large sampling area (Upper Tennessee River
Basin), and objective to keep method costs to a minimum,
standard addition was chosen to quantify all compounds in
the method. Although standard addition can be performed
with only one spiked sample [37], our method utilized a four
point linear regression. All analytes displayed excellent lin-
earity (r2 ≥ 0.995) when analyzed as neat standard solutions.
Further, each sample was amended with an IS to correct for small
variations in pipetting and sample injection volume. Response
factors were only calculated within individual samples because
the individual matrix of each sample influenced the IS differ-
ently.
Finally, all concentrations were corrected for recovery to
determine final concentrations by dividing the calculated con-
centration by the percent recovery. The majority of methods in
the peer reviewed literature for determination of pharmaceu-
ticals in environmental matrices do not indicate whether final
concentrations were corrected for recovery or not. Of the meth-
ods cited in this paper, only Lee et al. [25] indicate that they
did not correct for recovery. We conclude that the acceptably
low variation in recovery (<16%, n = 12 across 3 days) allowed
it to be used as a correction factor in the final determination of
pharmaceutical concentrations in environmental sample analy-
sis.
3.7. Analytical limitations
Instrumental limits of detection and quantitation (LOD and
LOQ) were defined as a signal to noise ratio of 3 and 10, respec-
tively. LODs and LOQs were calculated by analyzing a low
concentration standard solution (0.5g/L or 0.1g/L), using
software assisted techniques to calculate a signal to noise ratio
(Peak to Peak algorithm in Mass Lynx), and extrapolating to
the defined ratios for LOD and LOQ. For each analyte the low-
est concentration that resulted in a definable peak was used.
Each response was corrected by subtracting the signal-to-noise
ratio of any peaks present in blanks from the signal-to-noise
ratio of the standard solution. Finally, the units were normalized
from g/L to pg/injection for comparison with other methods.
LOD (range, 0.0452–1.27 pg/inj.; mean, 0.571 pg/inj.) and LOQ
(range, 0.151–4.22 pg/inj.; mean, 1.90 pg/inj.) values were as
low or lower when compared to other LC–MS/MS methods for
pharmaceuticals reporting pg/injection [17,20–22,24].
Method detection limits (MDL) are the most useful indicators
of the overall utility of an analytical method. The EPA defines
an MDL as the minimum concentration of a substance that can
be measured and reported with 99% confidence that the analyte
concentration is greater than 0 [41]. In the present study 10 repli-
cate samples (500 mL) of Tennessee River water were spiked at
10 ng/L and 10 were unspiked in order to subtract background
levels of analytes. Each spike and blank was processed, ana-
lyzed, and quantified according to the present method. Mean
concentration of each analyte was calculated for the 10 replicate
blanks and subtracted from each of the spiked samples. Next, the
standard deviation (S) was calculated for the blank subtracted
spiked samples and that value was used to determine the MDL
using the equation:
MDL = T(n−1,α=0.01) × S
where T = 2.821 for 9 degrees of freedom at α = 0.01. MDL val-
ues (range, 1.25–17.7 ng/L; mean, 4.08 ng/L) were also in the
same order of magnitude (low ng/L) as other similar methods
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[18,21,24,25] and adequately low for analysis of surface water
samples.
3.8. Environmental assessment and method application
The method was applied to surface water samples collected
from the Upper Tennessee River located in east Tennessee. The
sampling paradigm involved collecting surface water samples
upstream and downstream of major sewage treatment plants that
discharge directly into the Tennessee River between Knoxville,
TN and Chattanooga, TN. Table 4 presents the raw values as
quantified using the method.
Seven of the 14 analytes were detected (detection indicat-
ing a concentration ≥MDL) in at least one sample. Those
not detected include ciprofloxacin, diltiazem, fluoxetine, lev-
ofloxacin, norfluoxetine, ranitidine, and sertraline (Table 4).
Caffeine, carbamazepine, and sulfamethoxazole were the most
frequently detected pharmaceuticals with concentrations being
detected in all samples. Trimethoprim was detected in 3 out
of 10 samples. The remaining drugs (acetaminophen, atorvas-
tatin, and lovastatin) were detected in 1 out of 10 samples. To
our knowledge, the detection of lovastatin (18.3 ng/L) represents
the first time this compound has been detected in surface water
[16].
Caffeine displayed the highest mean reported concentration
(mean of all samples ± standard error, 28.9 ± 1.39 ng/L) as well
as the single highest concentration (38.8 ng/L). This is similar
to other studies analyzing for caffeine and is most likely due to
the non-prescription status of caffeine and its inclusion in many
common consumable products [18,20]. Sulfamethoxazole had
the second highest mean concentration (7.90 ± 0.32 ng/L), car-
bamazepine was third (4.62 ± 0.16 ng/L), and trimethoprim was
fourth (4.09 ± 1.20 ng/L). Sulfamethoxazole, trimethoprim, and
Table 4
Pharmaceutical concentrations (ng/L) in Tennessee River surface water collected
upstream (US) and downstream (DS) of five sewage treatment plants
SITE AMN CAF TMP SMZ CAB ATV LOV
1
US – 31.2 7.00 6.96 4.58 – 18.3
DS – 29.1 – 7.93 5.62 – –
2
US – 23.6 – 8.03 4.30 – –
DS – 23.2 – 7.92 4.41 – –
3
US 2.24 26.4 – 9.51 4.09 10.3 –
DS – 26.5 – 8.75 4.34 – –
4
US – 38.8 – 5.81 4.03 – –
DS – 32.3 – 7.47 4.92 – –
5
US – 30.4 2.41 9.03 4.57 – –
DS – 27.5 2.85 7.61 5.38 – –
Only those drugs with concentrations above their respective MDL are reported.
No detection is reported as (–). AMN, acetaminophen; CAF, caffeine; TMP,
trimethoprim; SMZ, sulfamethoxazole; CAB, carbamazepine; ATV, atorvas-
tatin; LOV, lovastatin.
carbamazepine have all been reported to be commonly detected
in STP impacted surface waters [17,18,20,21]. The remaining
drugs did not have sufficient detections to calculate means and
standard errors.
Field blanks displayed no detectable concentrations of phar-
maceuticals above their respective MDLs. The only exception
was atorvastatin, which displayed detection above the MDL in
the field blank. This was most likely an artifact and not indica-
tive of carryover. No consecutive samples displayed detections
of atorvastatin and the site where the field blank was prepared
also did not display detection of atorvastatin. This indicates that
no carryover from site to site occurred. In addition, on-going
field sampling has not indicated detection of atorvastatin in any
field blanks (data not shown). Method blanks were all below
MDL for every compound in the method. Method spikes were
within 20% of the reported recoveries indicating the acceptable
stability of freezing the samples at −80 ◦C between filtration
and SPE.
The sampling effort and environmental concentrations
reported here are parts of a larger field study of pharma-
ceuticals in the Upper Tennessee River Basin. The purpose
of the full study is to investigate spatial and temporal varia-
tions in pharmaceutical concentrations and relate those to an
indicator of aquatic invertebrate community health. The data
represented here have not been statistically tested for differ-
ences in upstream versus downstream sampling sites as this
will be performed at a later date with the complete dataset. The
purpose of the present study was to describe and evaluate the
analytical method and apply it to an initial sampling effort to
determine if the method was reliable and reproducible under
field conditions.
4. Conclusions
The LC–MS/MS method presented is rapid, relatively simple,
and minimally cost intensive as compared to similar methods.
The efficiency of the LC instrumentation employed allowed
for significant reductions in sample analysis time and vol-
ume of mobile phase employed. Also, the use of smaller SPE
sorbent masses with minimal elution volume, yet adequate
recovery and acceptable variation, resulted in decreased costs
associated with sample preparation. Further, the utility of the
standard addition method to accurately quantify compounds in
variable, complex sample matrices is cost favorable when com-
pared to expensive, and often unavailable, isotopically labeled
standards. The method has been validated through quality assur-
ance/quality control assessment and applied to a collection of
surface water samples. Levels of detected compounds are well
within reason (low ng/L) as compared to other studies in the
peer reviewed literature. Our results indicate that detectable
levels of at least seven commonly used prescription and non-
prescription pharmaceuticals are present in the Upper Tennessee
River. Future sampling efforts will focus on elucidating spa-
tial and temporal variations in pharmaceutical concentrations
as well as potential toxicological effects on aquatic organ-
isms.
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